Xiuting Hu1, Wei Cheng2, Shengxian Fan3, Yuhua Huang4, Xi Chen5, Zhiwei Jiang6, Jian Wang7,8. 1. State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, 163, Xianli Avenue, Nanjing, 210000, China. 2. Department of General Surgery, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210000, China. 3. Department of General Surgery, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, 210008, China. 4. Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210000, China. 5. State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, 163, Xianli Avenue, Nanjing, 210000, China. xichen@nju.edu.cn. 6. Department of General Surgery, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210000, China. fsyy00630@njucm.edu.cn. 7. Department of General Surgery, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, 210008, China. jianwangnju@yeah.net. 8. Department of Surgery, Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, 210000, China. jianwangnju@yeah.net.
Abstract
BACKGROUND: Previous studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data are available for intestinal fungal dysbiosis. Moreover, no effective therapeutic drugs are available for these microbiota dysbiosis. The aims of our study were to investigate the therapeutic potential of glucagon-like peptide 2 (GLP-2) for these microbiota dysbiosis in type 2 SBS rats. METHODS: 8-week-old male SD rats which underwent 80% small bowel resection, ileocecum resection, partial colon resection and jejunocolostomy, were treated with saline (SBS group, n = 5) or GLP-2 (GLP2.SBS group, n = 5). The Sham group rats which underwent transection and re-anastomosis were given a saline placebo (Sham group, n = 5). 16S rRNA and ITS sequencing were applied to evaluate the colonic bacterial and fungal composition at 22 days after surgery, respectively. RESULTS: The relative abundance of Actinobacteria, Firmicutes and proinflammatory Proteobacteria increased significantly in SBS group rats, while the relative abundance of Bacteroidetes, Verrucomicrobia and Tenericutes decreased remarkably. GLP-2 treatment significantly decreased Proteus and increased Clostridium relative to the saline treated SBS rats. The diversity of intestinal fungi was significantly increased in SBS rats, accompanied with some fungi abnormally increased and some resident fungi (e.g., Penicillium) significantly decreased. GLP-2 treatment significantly decreased Debaryomyces and Meyerozyma, and increased Penicillium. Moreover, GLP-2 partially restored the bacteria-fungi interkingdom interaction network of SBS rats. CONCLUSION: Our study confirms the bacterial and fungal dysbiosis in type 2 SBS rats, and GLP-2 partially ameliorated these microbiota dysbiosis.
BACKGROUND: Previous studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data are available for intestinal fungal dysbiosis. Moreover, no effective therapeutic drugs are available for these microbiota dysbiosis. The aims of our study were to investigate the therapeutic potential of glucagon-like peptide 2 (GLP-2) for these microbiota dysbiosis in type 2 SBSrats. METHODS: 8-week-old male SD rats which underwent 80% small bowel resection, ileocecum resection, partial colon resection and jejunocolostomy, were treated with saline (SBS group, n = 5) or GLP-2 (GLP2.SBS group, n = 5). The Sham group rats which underwent transection and re-anastomosis were given a saline placebo (Sham group, n = 5). 16S rRNA and ITS sequencing were applied to evaluate the colonic bacterial and fungal composition at 22 days after surgery, respectively. RESULTS: The relative abundance of Actinobacteria, Firmicutes and proinflammatory Proteobacteria increased significantly in SBS group rats, while the relative abundance of Bacteroidetes, Verrucomicrobia and Tenericutes decreased remarkably. GLP-2 treatment significantly decreased Proteus and increased Clostridium relative to the saline treated SBSrats. The diversity of intestinal fungi was significantly increased in SBSrats, accompanied with some fungi abnormally increased and some resident fungi (e.g., Penicillium) significantly decreased. GLP-2 treatment significantly decreased Debaryomyces and Meyerozyma, and increased Penicillium. Moreover, GLP-2 partially restored the bacteria-fungi interkingdom interaction network of SBSrats. CONCLUSION: Our study confirms the bacterial and fungal dysbiosis in type 2 SBSrats, and GLP-2 partially ameliorated these microbiota dysbiosis.
Entities:
Keywords:
Dysbiosis; Glucagon-like peptide 2; Intestinal bacterial and fungal; Intestinotrophic hormone; Short bowel syndrome
Authors: Hannah G Piper; Di Fan; Laura A Coughlin; Evi X Ho; Margaret M McDaniel; Nandini Channabasappa; Jiwoong Kim; Minsoo Kim; Xiaowei Zhan; Yang Xie; Andrew Y Koh Journal: JPEN J Parenter Enteral Nutr Date: 2016-07-12 Impact factor: 4.016
Authors: Mathias L Richard; Giuseppina Liguori; Bruno Lamas; Giovanni Brandi; Gregory da Costa; Thomas W Hoffmann; Massimo Pierluigi Di Simone; Carlo Calabrese; Gilberto Poggioli; Philippe Langella; Massimo Campieri; Harry Sokol Journal: Gut Microbes Date: 2017-10-12
Authors: Sara Lemoinne; Astrid Kemgang; Karima Ben Belkacem; Marjolène Straube; Sarah Jegou; Christophe Corpechot; Olivier Chazouillères; Chantal Housset; Harry Sokol Journal: Gut Date: 2019-04-19 Impact factor: 23.059
Authors: Harry Sokol; Valentin Leducq; Hugues Aschard; Hang-Phuong Pham; Sarah Jegou; Cecilia Landman; David Cohen; Giuseppina Liguori; Anne Bourrier; Isabelle Nion-Larmurier; Jacques Cosnes; Philippe Seksik; Philippe Langella; David Skurnik; Mathias L Richard; Laurent Beaugerie Journal: Gut Date: 2016-02-03 Impact factor: 23.059